Status:
UNKNOWN
Metabolic and Infectious Complications Post Belatacept Conversion
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Kidney Transplant Infection
Cardiovascular Diseases
Eligibility:
All Genders
18-80 years
Brief Summary
The BELASWITCH study is a prospective single-centre study including all kidney transplant patients for whom a conversion from Tacrolimus to Belatacept has been decided by the transplant clinicians of ...
Eligibility Criteria
Inclusion
- Adult patients who have had a kidney transplant more than 6 months ago.
- Whose immunosuppression includes stable Tacrolimus (change in dose or dosage form allowed) for at least 3 months.
- Therapeutic plan to change Tacrolimus-based immunosuppression to Belatacept
- Having signed the consent of collection CRB04 - Nephrology Collection (last authorization number: AC-2019-3627) and the BELASWITCH protocol consent.
Exclusion
- Subjects under guardianship or deprived of liberty
- Patients who object to the use of their data and/or samples in the research
- Patients having received an immunosuppressive treatment different from the standard one (Tacrolimus, mycophenolate mofetil or Everolimus, corticosteroids)
- ABO and/or HLA incompatible kidney transplantation
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05316038
Start Date
June 1 2022
End Date
June 1 2024
Last Update
April 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.